Welcome and Keynote
    COVID, Obesity & Diabetes Update
    London, United Kingdom
    P1
    Presented Posters
    Development of severe gastroparesis and gastric food bezoar following administration of glucagon-like peptide 1-receptor agonist (GLP1-RA) therapy.
    Sydney, Australia
    P2
    Presented Posters
    Resistant Hypocalcemia in a patient after Roux-en-Y gastric bypass
    London, United Kingdom
    P3
    Presented Posters
    Gender Differences in Cardiometabolic Abnormalities across Different BMI Categories
    Tal-Qroqq, Malta
    P4
    Presented Posters
    Vitamin D Receptor (VDR) Polymorphisms & Metabolic Health Status in a Maltese Cohort
    Msida, Malta
    P5
    Presented Posters
    Energy expenditure trends in patients following roux-en-y gastric bypass surgery
    London, United Kingdom
    14:10 - 14:20 
    Session Changeover
    CD2.1
    Oral Communications
    Contribution of BMI to ethnic disparities in outcomes following hospitalisation for COVID-19
    London, United Kingdom
    CD2.2
    Oral Communications
    GLYCAEMIC VARIABILITY ASSESSED BY CONTINUOUS GLUCOSE MONITORING AFTER ROUX-EN-Y GASTRIC BYPASS VS. SLEEVE GASTRECTOMY
    London, United Kingdom
    14:50 - 15:00 
    Break
    Plenary
    Sarcopaenic obesity – how to diagnose and impact on treatment
    Nottingham, United Kingdom
    Plenary
    New developments in appetite research
    London, United Kingdom
    Plenary
    Weight stigma; implications for the patient-practitioner relationship
    Leeds, United Kingdom
    16:00 - 16:15 
    Session Changeover
    16:15 - 16:45 
    Sponsored Satellite Symposium - This is a promotional symposium session organised and funded by Novo Nordisk. The information is intended for UK Healthcare Professionals (HCPs) only.
    16:45 - 16:55 
    Closing ceremony and Award presentations
    Chair: Professor Barbara McGowan (London, UK)
Rachel Agius
Tal-Qroqq, Malta
Thu 01 13:46
P3
Presented Posters
Gender Differences in Cardiometabolic Abnormalities across Different BMI Categories
Tal-Qroqq, Malta
Layla Badawy
London, United Kingdom
Thu 01 14:20
CD2.1
Oral Communications
Contribution of BMI to ethnic disparities in outcomes following hospitalisation for COVID-19
London, United Kingdom
Hessa Boharoon
London, United Kingdom
Thu 01 13:38
P2
Presented Posters
Resistant Hypocalcemia in a patient after Roux-en-Y gastric bypass
London, United Kingdom
Juliana Chen
Sydney, Australia
Wed 30 16:00
CD1.1
Oral Communications
Weight loss maintenance through a multidisciplinary Healthy Weight Clinic in Australia.
Sydney, Australia
Georgios Dimitriadis
London, United Kingdom
Wed 30 16:15
CD1.2
Oral Communications
Liraglutide 3.0mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials – The LIPOSAX first UK real-world evidence study.
London, United Kingdom
Professor Nick Finer
London, United Kingdom
Wed 30 15:10
An update on Pharmaceutical Therapy & New Treatments
The future of anti obesity medication
London, United Kingdom
Dr Stuart Flint
Leeds, United Kingdom
Thu 01 15:40
Plenary
Weight stigma; implications for the patient-practitioner relationship
Leeds, United Kingdom
Dr Tony Goldstone
London, United Kingdom
Wed 30 13:10
A year in review - what are the highlights?
Developments in treatments for rare genetic obesities
London, United Kingdom
Dr Nicola Guess
London, United Kingdom
Wed 30 16:50
Debate - Eat less: Cut carbs or meal times?
Cutting Carbs For Weight Management
London, United Kingdom
Wed 30 17:00
Debate - Eat less: Cut carbs or meal times?
Live Debate
London, United Kingdom
Leicester, United Kingdom
Dr Jonathan Hazlehurst
Birmingham, United Kingdom
Wed 30 14:10
A year in review - what are the highlights?
Standardising care in the identification and management of patients with post bariatric surgery hypoglycaemia
Birmingham, United Kingdom
Su Yee Khoo
Sydney, Australia
Thu 01 13:30
P1
Presented Posters
Development of severe gastroparesis and gastric food bezoar following administration of glucagon-like peptide 1-receptor agonist (GLP1-RA) therapy.
Sydney, Australia
Professor Carel Le Roux
Dublin, Ireland
Wed 30 14:40
A year in review - what are the highlights?
Stratification of obesity phenotypes to optimise future therapy (IMI SOPHIA)
Dublin, Ireland
Khalefah Malallah
London, United Kingdom
Thu 01 14:35
CD2.2
Oral Communications
GLYCAEMIC VARIABILITY ASSESSED BY CONTINUOUS GLUCOSE MONITORING AFTER ROUX-EN-Y GASTRIC BYPASS VS. SLEEVE GASTRECTOMY
London, United Kingdom
Professor Kevin Murphy
London, United Kingdom
Thu 01 15:20
Plenary
New developments in appetite research
London, United Kingdom
Dr Nikolai Pace
Msida, Malta
Thu 01 13:54
P4
Presented Posters
Vitamin D Receptor (VDR) Polymorphisms & Metabolic Health Status in a Maltese Cohort
Msida, Malta
Dr Emma Redman
Leicester, United Kingdom
Wed 30 16:40
Debate - Eat less: Cut carbs or meal times?
Is time restricted eating superior to continuous dietary restraint for weight management?
Leicester, United Kingdom
Wed 30 17:00
Debate - Eat less: Cut carbs or meal times?
Live Debate
London, United Kingdom
Leicester, United Kingdom
Dr Mario Siervo
Nottingham, United Kingdom
Thu 01 15:00
Plenary
Sarcopaenic obesity – how to diagnose and impact on treatment
Nottingham, United Kingdom
Yasmin Tabbakh
London, United Kingdom
Thu 01 14:02
P5
Presented Posters
Energy expenditure trends in patients following roux-en-y gastric bypass surgery
London, United Kingdom
Professor John Wass
Oxford, United Kingdom
Wed 30 15:30
An update on Pharmaceutical Therapy & New Treatments
Obesity Services – The Future
Oxford, United Kingdom
Dr Martin Whyte
London, United Kingdom
Thu 01 13:00
Welcome and Keynote
COVID, Obesity & Diabetes Update
London, United Kingdom
Professor John Wilding
Liverpool, United Kingdom
Wed 30 13:40
A year in review - what are the highlights?
Semaglutide and beyond: An update on pharmacotherapy for obesity
Liverpool, United Kingdom

0 result(s) found.